RxSight, Inc. Files 8-K: Executive & Director Changes
Ticker: RXST · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1111485
| Field | Detail |
|---|---|
| Company | Rxsight, Inc. (RXST) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, regulation-fd
TL;DR
RxSight 8-K: Execs and board shake-up, plus comp details. Keep an eye on leadership changes.
AI Summary
On December 23, 2025, RxSight, Inc. filed an 8-K report detailing changes in its executive officers and board of directors. The filing also includes information regarding compensatory arrangements for certain officers and a Regulation FD disclosure. The company, formerly known as Calhoun Vision Inc., is incorporated in Delaware and operates in the ophthalmic goods sector.
Why It Matters
This filing indicates potential shifts in company leadership and governance, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive officers and directors can signal internal shifts that may affect company performance or strategy.
Key Numbers
- 001-40690 — Commission File Number (Identifies the company's filing with the SEC)
- 94-3268801 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- RxSight, Inc. (company) — Registrant
- Calhoun Vision Inc. (company) — Former company name
- Delaware (jurisdiction) — State of Incorporation
- 949-521-7830 (phone_number) — Registrant's Telephone Number
- December 23, 2025 (date) — Date of earliest event reported
FAQ
What specific changes occurred regarding directors or certain officers?
The filing indicates a reportable event concerning the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as detailed in Item 5.02.
What is the primary business of RxSight, Inc.?
RxSight, Inc. operates in the Ophthalmic Goods sector, as indicated by its Standard Industrial Classification code 3851.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 23, 2025.
What was RxSight, Inc. formerly known as?
RxSight, Inc. was formerly known as Calhoun Vision Inc., with a name change date of April 10, 2000.
What is the principal executive office address for RxSight, Inc.?
The principal executive offices of RxSight, Inc. are located at 100 Columbia Street, Suite 120, Aliso Viejo, California 92656.
Filing Stats: 932 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-12-23 17:21:44
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share RXST The Nasdaq Stock Mar
Filing Documents
- rxst-20251223.htm (8-K) — 46KB
- 0001193125-25-331151.txt ( ) — 146KB
- rxst-20251223.xsd (EX-101.SCH) — 23KB
- rxst-20251223_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The Company reports that the leadership transition of its Chief Financial Officer, as described in Item 5.02 of this Current Report on Form 8-K, does not affect the Company's outlook or expectations for full-year 2025, and the Company continues to execute against its strategic and operational priorities. This report contains forward-looking statements, including statements concerning Company's outlook or expectations for full-year 2025 and statements relating to the Company's expectations and outlook as it continues to execute on its strategic and operational priorities. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in our Quarterly Report on Form 10-Q for the three months ended September 30, 2025, filed with the SEC on November 5, 2025, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this report to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. The information referenced under I
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. RxSight, Inc. Date: December 23, 2025 By: /s/ Ron Kurtz, M.D. Ron Kurtz, M.D. Chief Executive Officer and President